1. Home
  2. LAW vs TSHA Comparison

LAW vs TSHA Comparison

Compare LAW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$4.67

Market Cap

274.2M

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.83

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
TSHA
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
274.2M
1.8B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
LAW
TSHA
Price
$4.67
$6.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$8.00
$11.63
AVG Volume (30 Days)
250.5K
2.6M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
5.56
EPS
N/A
N/A
Revenue
$156,849,000.00
$9,773,000.00
Revenue This Year
$11.23
N/A
Revenue Next Year
$10.60
$1,152.42
P/E Ratio
N/A
N/A
Revenue Growth
8.29
17.28
52 Week Low
$2.45
$1.85
52 Week High
$9.11
$6.76

Technical Indicators

Market Signals
Indicator
LAW
TSHA
Relative Strength Index (RSI) 59.43 70.56
Support Level $3.83 $4.39
Resistance Level $4.94 N/A
Average True Range (ATR) 0.31 0.40
MACD 0.07 0.03
Stochastic Oscillator 69.31 89.58

Price Performance

Historical Comparison
LAW
TSHA

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: